Ipsen Biopharmaceuticals, Inc.
NEWS
A partial clinical hold placed at the end of last year remains in effect and the company has opted to terminate a trial in patients with multiple osteochondromas.
Ipsen’s decision to pause dosing in its studies of palovarotene trials for patients with fibrodysplasia ossificans progressive (FOP) has hit the France-based company right in the pocketbook.
The company hopes to resume the trials following an assessment of data.
FerGene launched last month with a $570 million investment from Ferring and Blackstone Life Sciences.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Shares of France-based Ipsen are down more than 2% on the Euronext Paris exchange after the U.S. Food and Drug Administration placed a partial clinical hold on its investigational treatment for fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO).
It was a moderately busy week for clinical trial news. Here’s a look.
Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a Guided Self-rehabilitation Contract.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
JOBS
IN THE PRESS